Menu

Women Lose Vision After Stem Cell Treatment

The adipose-derived cells were injected into the patients’ eyes to treat age-related macular degeneration. 

Mar 17, 2017
Kerry Grens

WIKIPEDIA, TMHLEEThree women were blinded following a procedure involving the injection of adipose-derived stem cells into their eyes, according to a report in the New England Journal of Medicine today (March 16). The patients were looking for a treatment to abate age-related macular degeneration, but within days of the experimental therapy they suffered severe complications.

Such stem cell treatments—when taken from the patients’ own bodies—are largely unregulated by the US Food and Drug Administration, and also largely unproven. “There is little question that when the FDA is involved in regulatory oversight, it works in favor of patient safety,” Stanford University’s Jeffrey Goldberg, a coauthor of the paper, told STAT News. “That would have protected patients in cases like these.”

According to Kaiser Health News, a Florida-based company formerly known as Bioheart Inc. and now called U.S. Stem Cell, sponsored the experimental treatment, which the firm had listed on clinicaltrials.gov, featuring the stem-cell procedure. But there were serious flaws, according to Goldberg’s report, including a lack of safety data.

“Is this just the tip of the iceberg for negative stem cell clinic outcomes given that there are around 600 such clinics in the US today largely operating generally without FDA approvals, lacking preclinical data to support what they are doing, and experimenting on thousands of patients for profit?” Paul Knoepfler, a stem cell biologist at the University of California, Davis, School of Medicine, wrote in a blog post.

Another group of researchers concurrently reported in the New England Journal of Medicine having success implanting a sheet of retinal pigment epithelial cells, derived from induced pluripotent stem (iPS) cells, to treat macular degeneration in an elderly woman. Following treatment, the patient’s vision didn’t not worsen a year after treatment.

This experiment, in contrast to the one in Florida, was lauded as “a landmark” by Harvard Medical School’s George Daley, who spoke with NPR. “It’s the first time any patient has been treated with cellular derivatives of iPS cells. So it’s definitely a world first,” said Daley, who was not part of the study. (Researchers have also had some success implanting human embryonic stem cells to treat macular degeneration.)

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.